Benitec Biopharma Inc
NASDAQ:BNTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BNTC's latest stock split occurred on Jul 26, 2023
The company executed a 1-for-17 stock split, meaning that for every 17 shares held, investors received 1 new share.
Before the split, BNTC traded at 0.2032 per share. Afterward, the share price was about 3.53.
The adjusted shares began trading on Jul 26, 2023. This was BNTC's 4th stock split, following the previous one in Apr 15, 2020.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 20, 2026
|
|
Fast Fitness Japan Inc
TSE:7092
|
1-for-4554450
/4554450
|
2303 999999.9999 JPY | N/A |
|
Apr 17, 2026
|
M
|
Miwon Chemicals Co Ltd
KRX:134380
|
10-for-1
x10
|
147900 14790 KRW | 13550 13550 KRW |
|
Apr 17, 2026
|
S
|
Shenzhen Best of Best Holdings Co Ltd
SZSE:001298
|
1-for-1
x1
|
30.47 20.9438 CNY | 21.98 21.98 CNY |
|
Apr 17, 2026
|
P
|
Pt Harta Djaya Karya Tbk
IDX:MEJA
|
7-for-6
x1.1666666666667
|
118.0001 101.1429 IDR | 111 111 IDR |
|
Apr 17, 2026
|
|
Yesco Holdings Co Ltd
KRX:015360
|
5-for-1
x5
|
80000 16000 KRW | 16110 16110 KRW |
7092
015360
Benitec Biopharma Inc
Glance View
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
